series-a
Stage
1
Investors
About
TAG Therapeutics develops TELOBLOCK, an antisense nucleotide therapy that selectively inhibits the DNA damage response at short or damaged telomeres to prevent cellular senescence, with demonstrated efficacy in preclinical models of telomere biology disorders such as pulmonary fibrosis and bone marrow failure.
Explore TAG Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.